Novavax Inc. NVAX announced positive results on Tuesday from three vaccine trials, including one that targets both COVID-flu and one that targets flu alone. The third trial was a high dose COVID vaccine. Novavax reported that all three candidates showed a robust immune response during Phase 2 clinical trials, and a preliminary safety profile was reassuring. The company said that the stand-alone candidate influenza vaccine achieved statistically significant antibody responses for hemagglutination inhibitory (HAI). These were 31 to 56% greater than Fluad. The stand-alone COVID at the highest dose achieved statistically significant neutralization reactions that…